Cat.No：GM-88053MAB
Product ：Anti-IL31RA hIgG2 Reference Antibody (Nemobio)
Cat.No：GM-88053MAB
Product ：Anti-IL31RA hIgG2 Reference Antibody (Nemobio)
GM-88053MAB-1mg / 1 mg
GM-88053MAB-5mg / 5 mg
GM-88053MAB-25mg / 5 mg * 5 vials
GM-88053MAB-50mg / 50 mg
GM-88053MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Species Reactivity | Human |
Clone | Nemolizumab |
Source/Isotype | hIgG2, Kappa |
Application | Bioactivity-ELISA |
Specificity | Detects IL31RA |
Gene | IL31RA |
Other Names | CRL, CRL3, GLM-R, GLMR, GPL, IL-31RA, PLCA2, PRO21384, hGLM-R, zcytoR17 |
Gene ID | 133396 (human) |
Background | IL-31 is a cytokine that is initially produced by activated T cells, especially Th2 cells, and is closely related to pathological processes such as inflammatory skin diseases and pruritus. The IL-31 receptor complex consists of two major components: the cell-surface receptor IL-31RA (aka IL-31 receptor a) and the signaling transmembrane protein Oncostatin m receptor-like subunit (OSMR, also known as part of the LGR1/βc receptor) . After the formation of functional complexes, they can trigger inflammatory response and neuro-immune coupling by downstream signaling pathways (such as Jak/Stat, MAPK, PI3K-AKT, etc.) , and promote itch transmission and inflammatory response. The IL-31/IL-31RA pathway is widely recognized to play a central role in pruritus and inflammation in multiple skin diseases, especially in eczema (atopic dermatitis, AD) and certain chronic inflammatory skin diseases. Nemolizuma is a monoclonal antibody that targets IL-31RA. By blocking the binding of Il-31 to IL-31RA, downstream signaling pathways are inhibited, thereby alleviating itching and inflammatory responses. |
Storage | Store at 2-8°C short term (1-2 weeks). Store at ≤ -20°C long term.Avoid repeated freeze-thaw. |
Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
Cat.No：GM-88053MAB
Product ：Anti-IL31RA hIgG2 Reference Antibody (Nemobio)
GM-88053MAB-1mg / 1 mg
GM-88053MAB-5mg / 5 mg
GM-88053MAB-25mg / 5 mg * 5 vials
GM-88053MAB-50mg / 50 mg
GM-88053MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Species Reactivity | Human |
Clone | Nemolizumab |
Source/Isotype | hIgG2, Kappa |
Application | Bioactivity-ELISA |
Specificity | Detects IL31RA |
Gene | IL31RA |
Other Names | CRL, CRL3, GLM-R, GLMR, GPL, IL-31RA, PLCA2, PRO21384, hGLM-R, zcytoR17 |
Gene ID | 133396 (human) |
Background | IL-31 is a cytokine that is initially produced by activated T cells, especially Th2 cells, and is closely related to pathological processes such as inflammatory skin diseases and pruritus. The IL-31 receptor complex consists of two major components: the cell-surface receptor IL-31RA (aka IL-31 receptor a) and the signaling transmembrane protein Oncostatin m receptor-like subunit (OSMR, also known as part of the LGR1/βc receptor) . After the formation of functional complexes, they can trigger inflammatory response and neuro-immune coupling by downstream signaling pathways (such as Jak/Stat, MAPK, PI3K-AKT, etc.) , and promote itch transmission and inflammatory response. The IL-31/IL-31RA pathway is widely recognized to play a central role in pruritus and inflammation in multiple skin diseases, especially in eczema (atopic dermatitis, AD) and certain chronic inflammatory skin diseases. Nemolizuma is a monoclonal antibody that targets IL-31RA. By blocking the binding of Il-31 to IL-31RA, downstream signaling pathways are inhibited, thereby alleviating itching and inflammatory responses. |
Storage | Store at 2-8°C short term (1-2 weeks). Store at ≤ -20°C long term.Avoid repeated freeze-thaw. |
Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
